AOD-9604 Dosage Chart
AOD-9604 is a modified fragment of the C-terminal region (residues 176-191) of human growth hormone, studied for lipolytic activity without the glucose-related effects of full-length GH. It advanced through obesity trials by Metabolic Pharmaceuticals, though the Phase 2 program did not meet its primary weight endpoint (AOD9604 clinical program, 2000s).
Half-life
Short (~30-60 minutes)
Format
Injectable
Purity
≥99%
Protocols
3 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Standard Research Protocol
Dose
300mcg once daily (morning, fasted)
Duration
8-12 weeks
The most commonly cited research dose. Fasted morning administration is used so lipolytic signaling is not blunted by recent food. Reassess after 8 weeks.
Protocol 2
Split Research Protocol
Dose
300mcg AM + 300mcg pre-fasted-cardio
Duration
6-10 weeks
Second dose timed before fasted activity in some research protocols. Total daily exposure stays in the low research range.
Protocol 3
Maintenance Protocol
Dose
300mcg 3-4 times per week
Duration
Ongoing (cycled)
Reduced-frequency dosing after an initial phase to lower cumulative exposure.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
5mg vial
BAC water
2ml bacteriostatic water
Concentration
2.5mg/ml (2500mcg/ml)
Dose / ml
300mcg = 0.12ml
Syringe units
12 IU per 300mcg on a U-100 syringe
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: 2-8°C preferred, -20°C for extended storage. Reconstituted: refrigerate at 2-8°C and use within about 28 days. Protect from light. Bring to room temperature before injection.
Research Considerations
Cautions
- AOD-9604 is a research compound not approved for human use. Source only COA-verified material.
- Lipolysis data comes largely from preclinical work; the human obesity trials did not confirm meaningful weight loss versus placebo.
- It does not raise IGF-1 the way full GH secretagogues do, so do not expect GH-axis effects.
Ready to start your research
Get AOD-9604 from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy AOD-9604 nowResearch use only. Not medical advice. Browse all dosage charts